Trial
NCT02996448
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Autosomal-dominant Hyper-IgE Syndrome
Intervention
NDV-3A
Why stopped
Safety concerns led to early termination.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-30